• 1. A 52-year-old man with treatment-naïve CIDP responds to IVIg but requires infusions every 3 weeks to maintain strength. Which statement best reflects the current understanding of CIDP pathophysiology and an unmet need in its management?*
  • 2. In the phase 2 study of riliprubart, a humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway, which finding best supports its potential for long-term disease control across varied CIDP populations?*
  • 3. A patient with CIDP has an inadequate response to IVIg despite dose optimization. Based on best practices for individualizing emerging complement-targeted therapy, which approach is most appropriate?*
  • Which of the following best describes your title?*

  • Please rate the extent to which this activity met the following objectives:

  • Learning Objectives
    Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • This educational activity will result in a change in my practice behavior.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
  • Attestation to time spent on activity: AcademicCME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

  • AcademicCME thanks you for your participation in this activity. All information provided improves the scope and purpose of our programs.

  • Should be Empty: